# A Study To Compare Effects Of GSK189075 In Combination With Either Furosemide Or Hydrochlorothiazide

> **NCT00671424** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 48 (estimated)

## Conditions studied

- Type 2 Diabetes Mellitus
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Hydrochlorothiazide (HCTZ)
- **DRUG:** Remogliflozin etabonate (GSK189075)
- **DRUG:** Furosemide

## Key facts

- **NCT ID:** NCT00671424
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2008-05
- **Final completion:** 2008-05
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2012-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00671424

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00671424, "A Study To Compare Effects Of GSK189075 In Combination With Either Furosemide Or Hydrochlorothiazide". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00671424. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*